Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.

For decades, a diagnosis of glioblastoma – an aggressive, hard-to-treat cancer in the brain – has been a death sentence for patients. Only 3% to 5% of people who are diagnosed with this type of brain ...

Promising mouse studies and billions of dollars in funding are stoking excitement. But we’ve been here before. Earlier this week, Life Biosciences, a biotech company focused on reversing age-related ...